Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women

Human Reproduction

Volumn 20, Issue 7, 2005, Pages 1833-1836

  Ibáñez, Lourdes ^a   Jaramillo, Adriana ^a   Ferrer, Angela ^a   de Zegher, Francis ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Androgen; Androgen receptor; Flutamide; Hepatotoxicity; PCOS

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; DROSPIRENONE; FLUTAMIDE; GESTODENE; LEUPRORELIN; METFORMIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FUTUROLOGY; HUMAN; HYPERANDROGENISM; LIVER FUNCTION TEST; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; OBESITY; OVARY POLYCYSTIC DISEASE;

EID: 21644478010     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/dei004     Document Type: Article

References (26)

1. Andrade RJ, Lucena MI, Fernandez MC, Suarez F, Montero JL, Fraga E and Hidalgo F (1999) Fulminant liver failure associated with flutamide therapy for hirsutism. Lancet 353,983.
2. Ferriman D and Gallwey JD (1961) Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21,1440-1447.
3. Gomez JL, Dupont A, Cusan L, Tremblay M, Suburu R, Lemay M and Labrie F (1992) Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med 92,465-470.
4. Ibáñez L and de Zegher F (2003a) Flutamide-metformin to reduce fat mass in hyper-insulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception. J Clin Endocrinol Metab 88,4720-4724.
5. Ibafañez L and de Zegher F (2003b) Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome. Hum Reprod 18,57-60.
6. Ibáñez L and de Zegher F (2004) Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and young women with hyper-insulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 89,1592-1597.
7. Ibáñez L and de Zegher F (2005) Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and anti-atherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. J Clin Endocrinol Metab 90,39-43.
8. Ibáñez L, Potau N, Zampolli M, Riqué S, Saenger P and Carrascosa A (1997) Hyperinsulinemia and decreased insulin-like growth factor binding protein-1 are common features in prepubertal and pubertal girls with a history of premature pubarche. J Clin Endocrinol Metab 82,2283-2288.
9. Ibañez L, Potau N, Marcos MV and de Zegher F (2000) Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. J Clin Endocrinol Metab 85,3251-3255.
10. Ibáñez L, Valls C, Potau N, Marcos MV and de Zegher F (2001) Polycystic ovary syndrome after precocious pubarche: ontogeny of the low birth-weight effect. Clin Endocrinol 55,667-672.
11. Ibañez L, Valls C, Ferrer A, Ong K, Dunger DB and De Zegher F (2002) Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. J Clin Endocrinol Metab 87,2870-2874.
12. Ibañez L, Ong K, Ferrer A, Amin R, Dunger D and de Zegher F (2003) Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. J Clin Endocrinol Metab 88,2600-2606.
13. Ibáñez L, Valls C, Cabré S and de Zegher F (2004a) Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and anti-atherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide. J Clin Endocrinol Metab 89,4716-4720.
14. Ibáñez L, Ferrer A, Ong K, Amin R, Dunger D and de Zegher F (2004b) Insulin sensitization early post-menarche prevents progression from precocious pubarche to polycystic ovary syndrome. J Pediatr 144,23-29.
15. Labrie F, Dupont A, Giguere M, Borsanyi JP, Lacourciere Y, Belanger A, Lachance R, Emond J and Monfette G (1988) Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer. Prog Clin Biol Res 260,41-62.
16. Muderris II, Bayram F and Guven M (2000) Treatment of hirsutism with lowest-dose flutamide (62.5 mg/day). Gynecol Endocrinol 14,38-41.
17. New MI, Lorenzen F, Lerner AJ, Kohn B, Oberfield SE, Pollack MS, Dupont B, Stoner E, Levy DJ, Pang S and Levine LS (1983) Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab 56,320-325.
18. 5-steroid levels. J Clin Endocrinol Metab 81, 3961-3965.
19. Singh SM, Gauthier S and Labrie F (2000) Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr Med Chem 7, 211-247.
20. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20,1183-1197.
21. Thole Z, Manso G, Salgueiro E, Revuelta P and Hidalgo A (2004) Hepatotoxicity induced by antiandrogens: a review of the literature. Urol Int 73,289-295.
22. Venturoli S, Paradisi R, Bagnoli A, Colombo FM, Ravaioli B, Vianello F, Mancini F, Gualerzi B, Porcu E and Seracchioli R (2001) Low-dose flutamide (125 mg/day) as maintenance therapy in the treatment of hirsutism. Horm Res 56,25-31.
23. Vidal-Puig A and Moller DE (1997) Insulin resistance: Classification, prevalence, clinical manifestations, and diagnosis. In Azziz R, Nestler JE, and Dewailly D (eds) Androgen Excess Disorders in Women. Lippincott-Raven Publishers, Philadelphia, USA, pp. 227-236.
24. Wallace C, Lalor EA and Chik CL (1993) Hepatotoxicity complicating flutamide treatment of hirsutism. Ann Intern Med 119,1150.
25. Wysowski DK and Fourcroy JL (1996) Flutamide hepatotoxicity. J Urol 155,209-212.
26. Wysowski DK, Freiman JP, Tourtelot JB and Horton ML, 3rd (1993) Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med 118,860-864.